Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

TalkMarkets Nov. 27 at 5:53 PM

3 Dividend-paying Stocks That Are Up Over 30% In 2025 $IBM $AMGN $ABBV https://talkmarkets.com/content/stocks--equities/3-dividend-paying-stocks-that-are-up-over-30-in-2025?post=541165

0 · Reply

MoneyGroupLLC Nov. 27 at 3:53 PM

Enter: $ABBV Calls Strike Price: $230 Expiry Date: DEC 19 2025 Buy in Price: $7.30 - $7.85 Sell Price: $15.55 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Czreri1 Nov. 27 at 3:43 PM

$ABBV Medicare cuts were steeper than expected for Linzess and Vraylar looks like for the drop.

0 · Reply

Tokenist Nov. 27 at 3:13 PM

🔥 3 Dividend Tanks Crushing 2025 — All Up 30%+ AND Paying You If you want growth + income, three stocks are absolutely dominating: $ABBV, $AMGN, and $IBM — each up 30%+ YTD while still pumping reliable dividends. 💰📈 💊 $ABBV — +32% YTD Huge cash flow, strong pipeline, ~3.5% yield. Keeps proving the doubters wrong. 🧬 $AMGN — +36% YTD FDA wins + obesity drug hype. Nearly 3% yield and a monster pipeline behind it. 🤖 $IBM — +41% YTD The surprise AI/quantum comeback. Big revenue beats, massive AI demand, and still paying dividends. Three blue-chip beasts delivering gains AND steady income. These aren’t meme pops, they’re dividend machines built to run. 🚀

1 · Reply

Czreri1 Nov. 26 at 10:35 PM

$ABBV why is this dropping every day.

1 · Reply

BrettAshcroftGreenSA Nov. 26 at 8:59 PM

$SCHD $MRK $ABBV $BMY

0 · Reply

mark90 Nov. 26 at 6:25 PM

$ABBV Very low volume.

0 · Reply

Buzzdaq Nov. 26 at 5:20 PM

$ABBV Dec5 235c (.96)

1 · Reply

ZacksResearch Nov. 26 at 4:23 PM

Which pharma giant is better positioned heading into 2026 — $ABBV or $PFE? ABBV’s surging immunology sales and its smoother LOE path are the clear standouts as both companies move toward a pivotal 2026. Full breakdown here 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-teaser-22598&ADID=SYND_STOCKTWITS_TWEET_2_2796033_TEASER_22598

1 · Reply

ZacksResearch Nov. 26 at 3:23 PM

$ABBV vs. $PFE: Which Pharma Giant Wins the Growth Battle? 💊 AbbVie is overcoming Humira's LOE with strong sales from Skyrizi & Rinvoq, expecting mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029. Meanwhile, Pfizer faces a challenging LOE cliff impacting revenues from 2026-2030, despite expected 6% CAGR in revenues from 2025 to 2030. Discover why ABBV might be the stronger pick for growth-focused investors 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-body-22585&ADID=SYND_STOCKTWITS_TWEET_2_2796033_BODY_22585

1 · Reply

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 3 days ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:25 AM EST - 3 days ago

5 Dividend Stocks to Hold for the Next 10 Years

ARCC ENB O VZ

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 9 days ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 9:00 AM EST - 9 days ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Nov 18, 2025, 8:25 AM EST - 9 days ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

Nov 17, 2025, 7:17 AM EST - 10 days ago

AbbVie Stock Falls 4% -- What Investors Need to Know

Nov 15, 2025, 7:25 AM EST - 12 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

ENB O

Nov 14, 2025, 4:31 PM EST - 12 days ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 3:19 PM EST - 13 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

Nov 13, 2025, 8:30 AM EST - 14 days ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 3:55 AM EST - 14 days ago

2 Strong Healthcare Stock Picks for Dividend Investors

JNJ

Nov 12, 2025, 3:06 PM EST - 15 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 8:30 AM EST - 15 days ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 15 days ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 11, 2025, 10:40 PM EST - 15 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:50 AM EST - 16 days ago

Three Healthcare Buys That Wall Street Loves

AMGN LLY

Nov 11, 2025, 8:49 AM EST - 16 days ago

5 Top Stocks to Buy in November

Nov 9, 2025, 11:05 AM EST - 18 days ago

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.

CVS UNH

Nov 9, 2025, 4:21 AM EST - 18 days ago

Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now

LMT PYPL

Nov 8, 2025, 6:38 AM EST - 19 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Nov 6, 2025, 8:45 AM EST - 21 days ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

CL ZTS

Nov 4, 2025, 5:15 AM EST - 23 days ago

2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon

MDT

Nov 3, 2025, 9:58 AM EST - 24 days ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

Nov 3, 2025, 7:30 AM EST - 24 days ago

My Favorite Dividend King to Buy in November

Nov 2, 2025, 9:15 AM EST - 25 days ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

ZTS

Nov 1, 2025, 11:15 PM EDT - 25 days ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Nov 1, 2025, 10:25 AM EDT - 26 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

Nov 1, 2025, 6:15 AM EDT - 26 days ago

Why AbbVie Stock Flopped on Friday

Oct 31, 2025, 3:56 PM EDT - 27 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 11:47 AM EDT - 27 days ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 10:39 AM EDT - 27 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 8:42 AM EDT - 27 days ago

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:20 AM EDT - 27 days ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 7:54 AM EDT - 27 days ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:49 AM EDT - 27 days ago

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 29, 2025, 5:00 PM EDT - 4 weeks ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 8:11 AM EDT - 4 weeks ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Oct 29, 2025, 5:11 AM EDT - 4 weeks ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH

Oct 28, 2025, 11:28 AM EDT - 4 weeks ago

AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 10:40 AM EDT - 4 weeks ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

GILD LLY MRK

Oct 28, 2025, 6:26 AM EDT - 4 weeks ago

Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?

Oct 26, 2025, 11:21 AM EDT - 4 weeks ago

Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade

AAPL

Oct 23, 2025, 1:07 PM EDT - 5 weeks ago

AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth

Oct 22, 2025, 7:00 PM EDT - 5 weeks ago

AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector

Oct 21, 2025, 2:27 PM EDT - 5 weeks ago

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

APTV PANW QCOM

Oct 21, 2025, 8:00 AM EDT - 5 weeks ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Oct 20, 2025, 8:12 AM EDT - 5 weeks ago

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Oct 20, 2025, 8:00 AM EDT - 5 weeks ago

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Oct 17, 2025, 4:34 PM EDT - 5 weeks ago

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

TalkMarkets Nov. 27 at 5:53 PM

3 Dividend-paying Stocks That Are Up Over 30% In 2025 $IBM $AMGN $ABBV https://talkmarkets.com/content/stocks--equities/3-dividend-paying-stocks-that-are-up-over-30-in-2025?post=541165

0 · Reply

MoneyGroupLLC Nov. 27 at 3:53 PM

0 · Reply

Czreri1 Nov. 27 at 3:43 PM

$ABBV Medicare cuts were steeper than expected for Linzess and Vraylar looks like for the drop.

0 · Reply

Tokenist Nov. 27 at 3:13 PM

1 · Reply

Czreri1 Nov. 26 at 10:35 PM

$ABBV why is this dropping every day.

1 · Reply

BrettAshcroftGreenSA Nov. 26 at 8:59 PM

$SCHD $MRK $ABBV $BMY

0 · Reply

mark90 Nov. 26 at 6:25 PM

$ABBV Very low volume.

0 · Reply

Buzzdaq Nov. 26 at 5:20 PM

$ABBV Dec5 235c (.96)

1 · Reply

ZacksResearch Nov. 26 at 4:23 PM

1 · Reply

ZacksResearch Nov. 26 at 3:23 PM

1 · Reply

TruthBroker2 Nov. 26 at 2:52 PM

$ABBV $SMMT

0 · Reply

BrettAshcroftGreenSA Nov. 26 at 2:28 PM

Dividends are real. The price drop on payout day doesn’t change earnings, which means valuation improves. That’s why funds like $SCHD matter — consistent dividend growers, strong ROE, solid free cash flow, and disciplined rebalancing. The fund is shifting toward undervalued Health Care names like $MRK $ABBV $BMY as the sector wakes up. With rates trending lower, qualified dividends become more attractive vs. cash yields. $SCHD sits near 10-year-high starting yields while REITs, MLPs, and staples trade at big discounts. Dividend value is back on sale. https://seekingalpha.com/article/4847759-schd-why-dividends-are-real

0 · Reply

TruthBroker2 Nov. 26 at 1:13 PM

$SMMT $ABBV

0 · Reply

Quantumup Nov. 26 at 12:22 PM

Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.

0 · Reply

ColinWolf981 Nov. 26 at 9:12 AM

$ABBV remains active in healthcare. AMBR will provide its Q3 results and corporate update via webcast November 26. https://viavid.webcasts.com/starthere.jsp?ei=1743886&tp_key=bebae2bd4a

0 · Reply

MoneyGroupLLC Nov. 26 at 5:57 AM

Enter: $ABBV Calls Strike Price: $230 Expiry Date: DEC 19 2025 Buy in Price: $5.95 - $6.15 Sell Price: $10.41 Profit : +75% (Turn every $1 into $1.75) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

WaveRB77 Nov. 26 at 2:17 AM

$ABBV green candle that's a hammer .Prices spike tomorrow.

0 · Reply

HedgeAlerts Nov. 26 at 1:56 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · DEC 05, 2025 Exp Entry Price: $2.53 - $2.83 Exit Price Target: $5.09 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Nov. 25 at 11:58 PM

1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $230 Call | Enter: $3.91 Exit: $6.31 | Profit: 61.20% ROI | https://1ightning.com

0 · Reply

TruthBroker2 Nov. 25 at 7:22 PM

$SMMT $ABBV

0 · Reply

dogDazeSummer Nov. 25 at 7:07 PM

$BIIB strikes again $50M up front. This time with an oral with “biological effect” https://www.biopharmadive.com/news/biogen-dayra-therapeutics-immunology-macrocyclic-peptides-versant-ventures/806269/ “The deal with Dayra centers around its oral macrocyclic peptides, which the company said have the “potential to offer biologic-like efficacy and safety in an oral format” compared to common infusion or injection immunology drugs. The molecules can also selectively target proteins associated with certain diseases, unlike traditional small molecule drugs that may have off-target effects.” $IFRX $ABBV

1 · Reply

Golden_Triangle_Capital Nov. 25 at 6:41 PM

$HALO Is $ABBV a potential buyer for $HALO?? I'm hearing rumblings...

0 · Reply

Market Cap	409.68B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	24.29
Forward PE	21.55
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	5,921,000
Avg Vol	6,281,506
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	9%
Beta	0.50
Analysts	Strong Sell
Price Target	$244.54